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Objectives: To search for biomarkers of RT-induced cardiotoxicity, we studied the behavior of ST2 during
RT and three years after RT, and the associations with echocardiographic changes.
Materials and methods: We measured soluble ST2 (ng/ml) in serum samples from 63 patients receiving
RT for early breast cancer. Sampling and echocardiography were performed at baseline, after RT and at
the three-year follow-up. Patients were grouped by >15% (group 1) and 15% (group 2) relative wors-
ening in global longitudinal strain (GLS).
Results: ST2 levels tended to increase during RT, from a median (interquartile range; IQR) of 17.9 (12.4
e22.4) at baseline to 18.2 (14.1e23.5) after RT (p ¼ 0.075). By the three-year follow up, ST2 levels
increased to 18.7 (15.8e24.2), p ¼ 0.018. The increase in ST2 level was associated with worsening cardiac
systolic function at three-year follow-up, GLS (rho ¼ 0.272, p ¼ 0.034) and left ventricular ejection
fraction (LVEF) (rho ¼ e0.343, p ¼ 0.006). Group 1 (n ¼ 14) had a signiﬁcant increase in ST2 levels from
17.8 (12.3e22.5) at baseline to 18.4 (15.6e22.6) after RT, p ¼ 0.035 and to 19.9 (16.0e25.1) three years
after RT, p ¼ 0.005. ST2 levels were stable in group 2 (n ¼ 47): 17.8 (12.3e22.0) at baseline, 17.7 (12.6
e23.5) after RT and 18.0 (15.5e22.4) at three years.
Conclusion: ST2 may be useful for determining which patients are at risk for long-term cardiovascular
toxicity following adjuvant breast cancer RT, but prospective clinical studies are needed to conﬁrm this
hypothesis.
© 2019 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Tampere University Hospital,
a.skytta@ﬁmnet.ﬁ (T. Skytt€a),




s article under the CC BY-NC-ND li1. Introduction
Adjuvant radiotherapy (RT) reduces breast cancer (BCa) recur-
rence and mortality [1,2], but the increase in long-term cardiac
morbidity and mortality caused by RT is of concern [3e9]. ST2 is
released by cardiomyocytes in response tomyocardial stress [10]. In
heart failure patients and in population-based studies, elevated
levels were associated with increased mortality [11e16]. No studies
on the effect of RT alone exist, but radiation exposure was associ-
ated with increased ST2 levels in nuclear plant workers [17].cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
ACE angiotensin converting enzyme inhibitor
AI aromatase inhibitor
ARB angiotensin II receptor blocker
ASA acetylsalicylic acid
BCa breast cancer
BMI body mass index
CAD coronary artery disease
DCIS ductal carcinoma in situ
GLS global longitudinal strain
IQR interquartile range
LAD left anterior descending coronary artery




LVEF left ventricular ejection fraction
RV right ventricle
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induced changes in left ventricular (LV) function in BCa patients, we
evaluated the behavior of ST2 and its association with LV systolic
function before RT, after RT and at the three-year follow-up.2. Materials and methods
This prospective, observational, single center study included 63
chemo-naïve patients with early-stage BCa or ductal carcinoma in
situ (DCIS) who received postoperative RT ± concurrent endocrine
therapy. Fifty patients had left-sided and 13 patients had right-
sided BCa. The key inclusion and exclusion criteria, and the RT
procedure were described in detail previously [18,19]. The local
ethics committee (R10160) approved the study and informed con-
sent was obtained from all participants.
Sampling and echocardiography were performed, as described
previously [20,21], at the start of RT (bRT), at the end of RT (eRT)
and at the three-year follow-up (3yRT). The concentrations of ST2
were measured by enzyme-linked immunosorbent assay with re-
agents from R&D Systems Europe Ltd. (Abingdon, UK). The detec-
tion limit and interassay coefﬁcient of variation were 7.8 pg/ml and
6.2%, respectively. N-terminal pro-brain natriuretic peptide
(proBNP) was measured at an accredited laboratory [22].2.1. Statistical analysis
The basic statistical testing was done as described previously
[23]. Multivariable linear regression analyses were performed to
model the change in GLS and in left ventricular ejection fraction
(LVEF) over three years, adjusting the models with the change in
ST2 over three years, age, body mass index (BMI), laterality of BCa,
aromatase inhibitor (AI) use and hypertension. Additionally, pa-
tients were divided into two groups: >15 and 15% relative change
in global longitudinal strain (GLS) [24], a clinically meaningful
change [24,25]. Differences between these groups were tested us-
ing multivariable logistic regression analysis, adjusting the model
with the change in ST2 over three years, AI use, age and the mean
dose to the left anterior descending coronary artery (LAD). Statis-
tical testing was performed utilizing IBM SPSS Statistics software,
version 25 for Windows (Armonk, NY, USA). P-values less than 0.05
were considered signiﬁcant.3. Results
3.1. Changes in ST2 levels and correlations with age, BMI and
proBNP
ST2 levels increased slightly from bRT to eRT and increased
signiﬁcantly from bRT to 3yRT (Table 1).
Age and the change in ST2 level during RT (Spearman’s rho
0.281, p ¼ 0.025), and BMI and the change in ST2 level during the
follow-up (rho 0.309, p ¼ 0.014) correlated. Furthermore, the
change in ST2 and proBNP levels during the follow-up were
correlated (rho 0.329, p ¼ 0.009).
3.2. The change in ST2 level and baseline characteristics
The change in ST2 level was signiﬁcantly greater patients with
hypertension during RT, p ¼ 0.008. Diabetic patients had higher
median ST2 levels at bRT than non-diabetic patients, p ¼ 0.025.
There were no other signiﬁcant differences according to other
baseline characteristics.
3.3. ST2 levels and systolic echocardiographic measurements
A table of echocardiographic parameters at bRT, eRT and at 3yRT
was published as a supplementary table in our previous publication
[23]. The change in ST2 levels during RTcorrelatedwith GLS at 3yRT
(rho ¼ 0.287, p ¼ 0.025). Furthermore, the change in ST2 level over
the three years was correlated with GLS (rho ¼ 0.272, p ¼ 0.034)
and LVEF (rho ¼ e0.343, p ¼ 0.006) at 3yRT.
In multivariable linear regression analyses, no variables signiﬁ-
cantly explained the decrease in LVEF, but AI use and left-sided BCa
were associated with the impairment in GLS over the follow-up,
p ¼ 0.042 and p ¼ 0.013, respectively. The change in ST2 level did
not quite reach signiﬁcance in the model, p ¼ 0.093. The variables
explained 24.3% of the variance.
3.4. Grouping according to >15% and 15% relative change in GLS
over three years
Patients were grouped according to a clinically meaningful GLS
change: 14 patients with >15% (group 1) and 47 patients with15%
(group 2) relative worsening in GLS. Group 1 had a signiﬁcant
worsening in GLS during RT, p ¼ 0.006, and during the follow-up,
p < 0.001 (Table 2). Group 2 had a stable GLS during RT,
p ¼ 0.979, and the follow-up, p ¼ 0.183.
The baseline characteristics, cardiac doses, GLS measurements
and ST2 levels are displayed in Table 2. The median ST2 level
increased signiﬁcantly only in group 1 during RT (p ¼ 0.035) and
the follow-up (p¼ 0.005). In group 2, the ST2 level remained stable,
p ¼ 0.220 during RT and p ¼ 0.500 during the follow-up.
In multivariable binary logistic regression analysis, AI users (OR
5.61 [95% CI 1.25e25.10]) were more likely to be in group 1.
Furthermore, increasing mean dose to LAD (OR 1.07 [95% CI
1.00e1.15]), greater increase in ST2 levels (OR 1.15 [95% CI
0.93e1.41]) and older age (OR 1.08 [95% CI 0.96e1.22]) nearly
reached signiﬁcance.
4. Discussion
We report a small, yet signiﬁcant, increase in ST2, a possible
marker of cardiotoxicity, three years after adjuvant RT for early BCa.
One earlier study found no association between RT and ST2 levels,
but the ST2 levels increased 6 months after chemotherapy, which
could have masked the effect of RT [26].
Older age, BMI, hypertension and diabetes affected ST2 levels,
Table 1
ST2 levels at the different time points for the entire study population (n ¼ 63).
Baseline After RT 3 years p1 p2
Md (IQR) Md (IQR) Md (IQR)
ST2 (ng/ml) 17.9 (12.4e22.4) 18.2 (14.1e23.5) 18.7 (15.8e24.2) 0.075 0.018
RT, radiotherapy; Md, median; IQR, interquartile range; p1, change from baseline to after RT; p2, change from baseline to the three-year follow-up.
Statistical signiﬁcance is shown in bold (p < 0.05).
Table 2
Baseline characteristics, cardiac doses, GLS and ST2 levels compared according to the >15% (group 1) and 15% (group 2) relative change in GLS.
Group 1 (n¼ 14) Group 2 (n¼ 47) p
Baseline characteristics
Age, Md (IQR) 67.0 (59.0e73.5) 64.0 (58.0e66.0) 0.049
BMI, Md (IQR) 28.8 (24.8e30.7) 25.8 (23.9e27.7) 0.081
Left-sided BC, n (%) 14 (100.0) 35 (74.5) 0.052
AI, n (%) 9 (64.3) 11 (23.4) 0.008
Tam, n (%) 0 (0.0) 6 (12.8) 0.321
Hypertension, n (%) 5 (35.7) 18 (38.3) 1.000
ACE, n (%) 3 (21.4) 13 (27.7) 0.742
Beta-blockers, n (%) 4 (28.6) 7 (14.9) 0.256
ASA, n (%) 1 (7.1) 4 (8.5) 1.000
Statins, n (%) 2 (14.3) 10 (21.3) 0.715
CAD, n (%) 1 (7.1) 2 (4.3) 0.549
Diabetes, n (%), n¼ 14 and 44 1 (7.1) 3 (6.8) 1.000
Smoking, n (%) 1 (7.1) 5 (10.6) 1.000
Hypothyreosis, n (%) 4 (28.6) 6 (12.8) 0.245
Radiation doses to the heart
Dmean heart 2 Gy, n (%) 11 (78.6) 23 (48.9) 0.068
Dmean heart (Gy); Md (IQR) 3.4 (2.0e4.0) 1.9 (1.0e3.8) 0.082
V20 Gy to heart (%); Md (IQR) 4.6 (1.5e5.3) 1.4 (0e4.5) 0.052
Dmean LV (Gy); Md (IQR) 4.6 (3.0e5.6) 2.7 (1.1e5.9) 0.148
V20 Gy to LV (%), Md (IQR) 6.8 (1.9e8.0) 1.8 (0e8.4) 0.150
Dmean RV (Gy), Md (IQR) 2.4 (1.7e3.0) 1.5 (1.0e2.9) 0.073
Dmean LAD (Gy), Md (IQR) 23.7 (10.5e28.9) 9.4 (1.4e24.8) 0.012
V20 GY to LAD (%), Md (IQR) 50.3 (14.7e71.9) 12.8 (0e55.0) 0.015
GLS at different time points
GLS baseline (%), Md (IQR) e20.0 (e23.3-e17.0) e17.0 (e19.0-e15.0) 0.036
GLS after RT (%), Md (IQR) e16.5 (e19.3-e14.8) e17.0 (e20.0-e15.0) 0.704
GLS at 3 years (%), Md (IQR) e14.0 (e16.3-e11.0) e18.0 (e20.0-e16.0) < 0.001
ST2 levels
ST2 baseline (ng/ml), Md (IQR) 17.8 (12.3e22.5) 17.8 (12.3e22.0) 0.803
ST2 after RT (ng/ml), Md (IQR) 18.4 (15.6e22.6) 17.7 (12.6e23.5) 0.561
ST2 at 3 years (ng/ml), Md (IQR) 19.9 (16.0e25.1) 18.0 (15.5e22.4) 0.383
GLS, global longitudinal strain; RT, radiotherapy; Md, median; IQR, interquartile range; BMI, body mass index; BC, breast cancer; AI, aromatase inhibitor;
ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, low dose acetylsalicylic acid; CAD, coronary artery disease;
Diabetes, use of diabetes medication; Dmean; mean dose to the structure; V20, the percentage of volume of the structure receiving 20 Gy; LV, left ventricle;
RV, right ventricle; LAD, left anterior descending coronary artery; p, p-value from the Mann-Whitney U test.
Statistical signiﬁcance is shown in bold (p < 0.05).
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tors are at a greater risk for cardiotoxicity. These associations have
been reported previously [16,27,28].4.1. ST2 levels and changes in LV systolic function
The increase in the ST2 level during RT was associated with a
higher, thus worse, GLS at the three-year follow-up. Additionally,
the three-year change in the ST2 level correlated with a worsening
in GLS and LVEF, both known prognostic factors for cardiovascular
death [29]. The association between worsening GLS and increasing
ST2 levels has been reported previously in patients with cardiac
conditions [30,31]. In multivariable analysis, the worsening in GLS
was predicted by AI use and left-sided BCa, an association we have
reported previously [19,21]. The change in ST2 level was only
suggestive in association with worsening GLS.
A signiﬁcant increase in ST2 level was found in patients with a
>15% relative worsening in GLS. In the multivariable analysis, only
AI use signiﬁcantly predicted the worsening of GLS. Theassociations between age, LAD radiation dose and the change in ST2
level during the follow-up and the change in GLS were hypothesis
generating.
4.2. Limitations
The small sample size is a limitation of our study. Furthermore,
the changes in LV systolic function and ST2 levels were subclinical
and a longer follow-up is needed to determine whether these
changes translate into clinically relevant cardiovascular risk.
5. Conclusion
We observed a small but signiﬁcant increase in ST2 levels during
adjuvant RT ± endocrine therapy for BCa and during the three-year
follow-up. The increase was apparent in patients with a >15%
worsening in GLS, which was also associatedwith AI use and higher
radiation dose to the LAD. As it takes years for RT-induced heart
disease tomanifest, longer follow-up and larger prospective clinical
H. Aula et al. / The Breast 49 (2020) 183e186186studies are needed to conﬁrm whether ST2 levels provide addi-
tional value in cardiotoxicity risk evaluation.
Ethical approval
The study was approved by the Tampere University Hospital
ethics committee (R10160), Tampere, Finland, and informed con-
sent was obtained from all participants.
Declarations of competing interest
None.
Acknowledgements
Ms. Salla Hietakangas is warmly acknowledged for her skillful
technical assistance.
Financial support was provided by the Seppo Nieminen Fund
(150620 and 150636), the Ida Montin Foundation (20180260), the
Finnish Society for Oncology, the Finnish Cultural Foundation
(Pirkanmaa Regional Fund 50181690), and the competitive state
ﬁnancing of the expert responsibility area of the Tampere Univer-
sity Hospital and the Paulo Foundation. The funding sources had no
role in study design; in the collection, analysis and interpretation of
data; in the writing of the report; or in the decision to submit the
article for publication.
References
[1] EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P,
Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mas-
tectomy and axillary surgery on 10-year recurrence and 20-year breast cancer
mortality: meta-analysis of individual patient data for 8135 women in 22
randomised trials. Lancet 2014;383:2127e35. https://doi.org/10.1016/S0140-
6736(14)60488-8.
[2] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S,
McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after
breast-conserving surgery on 10-year recurrence and 15-year breast cancer
death: meta-analysis of individual patient data for 10 801 women in 17
randomised trials. Lancet 2011;378:1707e16. https://doi.org/10.1016/S0140-
6736(11)61629-2.
[3] Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart dis-
ease and lung cancer after radiotherapy for early breast cancer: prospective
cohort study of about 300,000 women in US SEER cancer registries. Lancet
Oncol 2005;6:557e65. https://doi.org/10.1016/S1470-2045(05)70251-5.
[4] Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D,
et al. Risk of ischemic heart disease in women after radiotherapy for breast
cancer. N Engl J Med 2013;368:987e98. https://doi.org/10.1056/
NEJMoa1209825.
[5] Bouillon K, Haddy N, Delaloge S, Garbay J-R, Garsi J-P, Brindel P, et al. Long-
term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll
Cardiol 2011;57:445e52. https://doi.org/10.1016/j.jacc.2010.08.638.
[6] Hooning MJ, Botma A, Aleman BMP, Baaijens MHA, Bartelink H, Klijn JGM,
et al. Long-term risk of cardiovascular disease in 10-year survivors of breast
cancer. JNCI J Natl Cancer Inst 2007;99:365e75. https://doi.org/10.1093/jnci/
djk064.
[7] Harris EER, Correa C, Hwang W-T, Liao J, Litt HI, Ferrari VA, et al. Late cardiac
mortality and morbidity in early-stage breast cancer patients after breast-
conservation treatment. J Clin Oncol 2006;24:4100e6. https://doi.org/
10.1200/JCO.2005.05.1037.
[8] Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from
heart disease and lung cancer more than 20 years after radiotherapy for breast
cancer. Br J Canc 2013;108:179e82. https://doi.org/10.1038/bjc.2012.575.
[9] Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JCM,
et al. Cardiovascular disease risk in a large, population-based cohort of breast
cancer survivors. Int J Radiat Oncol 2016;94:1061e72. https://doi.org/
10.1016/j.ijrobp.2015.11.040.
[10] Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S,
Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor
family member, in cardiomyocytes and myocardial infarction. Circulation
2002;106:2961e6. https://doi.org/10.1161/01.cir.0000038705.69871.d9.
[11] Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL.
Usefulness of soluble concentrations of interleukin family member ST2 as
predictor of mortality in patients with acutely decompensated heart failure
relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259e67.https://doi.org/10.1016/j.amjcard.2010.09.011.
[12] Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, et al. Mea-
surement of the interleukin family member ST2 in patients with acute dys-
pnea. J Am Coll Cardiol 2007;50:607e13. https://doi.org/10.1016/
j.jacc.2007.05.014.
[13] Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. ACC/AHA/
HFSA focused update of the 2013 ACCF/AHA guideline for the management of
heart failure: a report of the American college of cardiology/American heart
association task force on clinical practice guidelines and the heart failure
society of amer. Circulation 2017 2017;136:e137e61. https://doi.org/10.1161/
CIR.0000000000000509.
[14] Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, et al.
Prognostic utility of novel biomarkers of cardiovascular stress: the Framing-
ham Heart Study. Circulation 2012;126:1596e604. https://doi.org/10.1161/
CIRCULATIONAHA.112.129437.
[15] Cheng JM, Akkerhuis KM, Battes LC, van Vark LC, Hillege HL, Paulus WJ, et al.
Biomarkers of heart failure with normal ejection fraction: a systematic review.
Eur J Heart Fail 2013;15:1350e62. https://doi.org/10.1093/eurjhf/hft106.
[16] Parikh RH, Seliger SL, Christenson R, Gottdiener JS, Psaty BM, DeFilippi CR.
Soluble ST2 for prediction of heart failure and cardiovascular death in an
elderly, community-dwelling population. J Am Heart Assoc 2016;5. https://
doi.org/10.1161/JAHA.115.003188.
[17] Katsarska O, Zaharieva E, Aneva N, Savova G, Stankova K, Boteva R. The sol-
uble receptor ST2 is positively associated with occupational exposure to ra-
diation. Int J Radiat Biol 2016;92:87e93. https://doi.org/10.3109/
09553002.2016.1115135.
[18] Tuohinen SS, Skytta T, Virtanen V, Luukkaala T, Kellokumpu-Lehtinen P-L,
Raatikainen P. Early effects of adjuvant breast cancer radiotherapy on right
ventricular systolic and diastolic function. Anticancer Res 2015;35:2141e7.
[19] Skytta T, Tuohinen S, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen P-L. The
concurrent use of aromatase inhibitors and radiotherapy induces echocar-
diographic changes in patients with breast cancer. Anticancer Res 2015;35:
1559e66.
[20] Tuohinen SS, Skytta T, Virtanen V, Virtanen M, Luukkaala T, Kellokumpu-
Lehtinen P-L, et al. Detection of radiotherapy-induced myocardial changes by
ultrasound tissue characterisation in patients with breast cancer. Int J Car-
diovasc Imaging 2016;32:767e76. https://doi.org/10.1007/s10554-016-0837-
9.
[21] Tuohinen SS, Skytta T, Poutanen T, Huhtala H, Virtanen V, Kellokumpu-
Lehtinen P-L, et al. Radiotherapy-induced global and regional differences in
early-stage left-sided versus right-sided breast cancer patients: speckle
tracking echocardiography study. Int J Cardiovasc Imaging 2017;33:463e72.
https://doi.org/10.1007/s10554-016-1021-y.
[22] Fimlab laboratories. www.ﬁmlab.ﬁ. [Accessed 13 September 2019].
[23] Aula H, Skytt€a T, Tuohinen S, Luukkaala T, H€am€al€ainen M, Virtanen V, et al.
Transforming growth factor beta 1 levels predict echocardiographic changes
at three years after adjuvant radiotherapy for breast cancer. Radiat Oncol
2019;14:155. https://doi.org/10.1186/s13014-019-1366-1.
[24] Tuohinen SS, Skytt€a T, Huhtala H, Virtanen V, Kellokumpu-Lehtinen P-L,
Raatikainen P. Left ventricular speckle tracking echocardiography changes
among early-stage breast cancer patients three years after radiotherapy.
Anticancer Res 2019;39:4227e36. https://doi.org/10.21873/anticanres.13584.
[25] Zamorano JL, Lancellotti P, Rodriguez Mu~noz D, Aboyans V, Asteggiano R,
Galderisi M, et al. ESC Position Paper on cancer treatments and cardiovascular
toxicity developed under the auspices of the ESC Committee for Practice
Guidelines. Eur J Heart Fail 2017 2016;19:9e42. https://doi.org/10.1002/
ejhf.654.
[26] Huang G, Zhai J, Huang X, Zheng D. Predictive value of soluble ST-2 for
changes of cardiac function and structure in breast cancer patients receiving
chemotherapy. Medicine (Baltim) 2018;97:e12447. https://doi.org/10.1097/
MD.0000000000012447.
[27] Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated
with all-cause and cardiovascular mortality in a population-based cohort: the
dallas heart study. Clin Chem 2013;59:536e46. https://doi.org/10.1373/
clinchem.2012.191106.
[28] Lin Y-H, Zhang R-C, Hou L-B, Wang K-J, Ye Z-N, Huang T, et al. Distribution and
clinical association of plasma soluble ST2 during the development of type 2
diabetes. Diabetes Res Clin Pract 2016;118:140e5. https://doi.org/10.1016/
j.diabres.2016.06.006.
[29] Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV
dysfunction: a systematic review and meta-analysis of global longitudinal
strain and ejection fraction. Heart 2014;100:1673e80. https://doi.org/
10.1136/heartjnl-2014-305538.
[30] Fabiani I, Conte L, Pugliese NR, Calogero E, Barletta V, Di Stefano R, et al. The
integrated value of sST2 and global longitudinal strain in the early stratiﬁ-
cation of patients with severe aortic valve stenosis: a translational imaging
approach. Int J Cardiovasc Imaging 2017;33:1915e20. https://doi.org/
10.1007/s10554-017-1203-2.
[31] Broch K, Leren IS, Saberniak J, Ueland T, Edvardsen T, Gullestad L, et al. Soluble
ST2 is associated with disease severity in arrhythmogenic right ventricular
cardiomyopathy. Biomarkers 2017;22:367e71. https://doi.org/10.1080/
1354750X.2016.1278266.
